Contact Us

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

An Active Pharmaceutical Ingredient (API) is the biologically active component of a drug that produces the intended effects. These ingredients are chemical or natural substances or a combination of substances used in a finished pharmaceutical products (FPP) intended to furnish pharmacological activity or to otherwise have a direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease, or to have direct effect in restoring, correcting or modifying physiological functions in human beings. Active pharmaceutical ingredients manufacturing process is a related series of operations which result in the preparation of active pharmaceutical ingredients. Major operations or steps in the API process may include multi-step chemical synthesis and fermentation, purification, crystallization, drying, milling, packing, labeling, and testing.

The global active pharmaceutical ingredients market is estimated to be valued at US$ 180.4 billion in 2020 and is expected to exhibit a CAGR of 6.7% during the forecast period (2020-2027).

Figure 1. Global Active Pharmaceutical Ingredients Market Share (%) in Terms of Value, By Region, 2020

Active Pharmaceutical Ingredients  | Coherent Market Insights

Factors such as the increasing prevalence of chronic diseases, and investments in research and development are expected to drive the market growth during the forecast period.

The growing prevalence of chronic diseases is expected to drive demand for drugs and fuel the global active pharmaceutical ingredients market growth in near future. According to the World Health Organization’s mortality and global health estimates of 2015, ischemic heart disease, stroke, chronic obstructive lung disease, and lower respiratory infections have been the cause for maximum number of deaths in the past decade.

Furthermore, increasing number of major pharmaceutical companies are focusing on expansion of their product lines in HPAPIs or considering investing in new HPAPIs production facilities, and further outsourcing manufacturing of APIs to contract manufacturers. For instance, in October 2017, Piramal Pharma Solutions (PPS), a contract development and manufacturing organization invested US$ 55 million across its sites in Asia to expand its API manufacturing capabilities and capacities.

request-sample

Active Pharmaceutical Ingredients Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 180.4 Bn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 6.7% 2027 Value Projection: US$ 284.3 Bn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Product Type: Low Potent APIs, High Potent APIs.
  • By Molecule Type: Small Molecules, Large Molecules.
  • By Formulation: Oral, Topical, Injectables, Drops.
  • By Application: Diabetes, Oncology, Cardiovascular, CNS, Analgesics, Ophthalmic, Respiratory, Dermatology, Others.
Companies covered:

Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Endo International plc, Dr. Reddy’s Laboratories Ltd., Novartis AG, Mylan N.V., Amneal Pharmaceuticals LLC, Lonza Group, Stada Arzneimittel AG, Lupin Limited, Fresenius Kabi, Hikma Pharmaceuticals, Aurobindo Pharma Limited, Apotex Inc., Cipla Limited, Taro Pharmaceutical Industries Ltd., Biological E. Limited, CordenPharma International, Evonik Industries AG, Sun Pharmaceutical Industries Ltd., Glenmark Pharma, and Krka Pharmaceuticals

Growth Drivers:
  • Increasing prevalence of chronic diseases
  • Geographic expansion of active pharmaceutical ingredient manufacturers in Asia
  • Increasing investment in research and development by manufacturers
Restraints & Challenges:
  • Strict Regulatory Scenario

Figure 2. Global Active Pharmaceutical Ingredients Market Share (%), by Product Type, 2020

Active Pharmaceutical Ingredients  | Coherent Market Insights

Geographic expansions by API manufacturers are expected to drive the market growth during the forecast period.

Several active pharmaceutical ingredients manufacturers are expanding their presence across the globe. API manufacturers are establishing their commercial production units in Asia Pacific to remain competitive and gain advantage over other competitors.

For instance, in May 2019, BASF and SINOPEC have started production at the propionic acid plant at the Verbund site, China. The new plant has an annual production capacity of 30,000 metric tons of propionic acid.

Global Active Pharmaceutical Ingredients Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus disease (COVID-19) has resulted in more than 58.6 million infected individuals worldwide as of November 23, 2020. As most API manufacturers are based in China and India, the global supply has been impacted significantly due to the COVID-19 outbreak in these countries. For instance, as per US FDA Center for Drug Evaluation and Research, total API demand from the U.S. biopharmaceutical companies is fulfilled by 230 API manufacturing facilities in China (13% of total supply facilities), 510 in the U.S. (28%), and remaining 59% or 1,048 facilities other countries. Manufacturing sites which are based in countries worst hit by COVID-19 have been affected severely due to severe shortage of medical resources and raw materials at these countries. This has led to global supply disruption.

Global Active Pharmaceutical Ingredients Market - Restraint

Stringent regulatory guidelines are expected to hinder growth of the global active pharmaceutical ingredients market. Stringent global regulatory policies on quality assessments of active pharmaceutical ingredients manufacturing, facility certification, enhanced cGMP guidelines tightening surprise inspection regimes, and increased supply chain security issues in emerging countries impacted cost of final active pharmaceutical ingredients products.

Key Players

Major players operating in the global active pharmaceutical ingredients market are Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Endo International plc, Dr. Reddy’s Laboratories Ltd., Novartis AG, Mylan N.V., Amneal Pharmaceuticals LLC, Lonza Group, Stada Arzneimittel AG, Lupin Limited, Fresenius Kabi, Hikma Pharmaceuticals, Aurobindo Pharma Limited, Apotex Inc., Cipla Limited, Taro Pharmaceutical Industries Ltd., Biological E. Limited, CordenPharma International, Evonik Industries AG, Sun Pharmaceutical Industries Ltd., Glenmark Pharma, and Krka Pharmaceuticals.

An active pharmaceutical ingredient is a chemical compound that is the most important raw material to produce a finished medicine. In medicine, API produces the intended effects to cure the disease. For instance, Paracetamol is the API for Crocin and it is the API that gives relief from body ache and fever. API is not made by only one reaction from the raw materials but rather it becomes an API via several chemical compounds. The chemical compound which is in the process of becoming an API from raw material is called an intermediate. Finished dosage forms manufacturers are now more focusing on API procurement from outsourcing due to cost effective products obtained through this API outsourcing.

Market Dynamics

Increasing research & development expenditure and rising incidence of chronic diseases are some of the major factors responsible for growth of the global active pharmaceutical ingredients market. According to the World Health Organization – Non-communicable Diseases (NCD) Country Profiles, around 269,500 premature deaths occurred due to non-communicable diseases (NCD) in South Africa in 2016.

Key features of the study:

  • This report provides in-depth analysis of the global active pharmaceutical ingredients market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global active pharmaceutical ingredients market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study are Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Endo International plc, Dr. Reddy’s Laboratories Ltd., Novartis AG, Mylan N.V., Amneal Pharmaceuticals LLC, Lonza Group, Stada Arzneimittel AG, Lupin Limited, Fresenius Kabi, Hikma Pharmaceuticals, Aurobindo Pharma Limited, Apotex Inc., Cipla Limited, Taro Pharmaceutical Industries Ltd., Biological E. Limited, CordenPharma International, Evonik Industries AG, Sun Pharmaceutical Industries Ltd., Glenmark Pharma, and Krka Pharmaceuticals.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global active pharmaceutical ingredients market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global active pharmaceutical ingredients market.

Detailed Segmentation:

  • Global Active Pharmaceutical Ingredients Market, By Product Type:
    • High Potent APIs
    • Low Potent APIs
  • Global Active Pharmaceutical Ingredients Market, By Molecule Type:
    • Small Molecules
    • Large Molecules
  • Global Active Pharmaceutical Ingredients Market, By Formulation:
    • Oral
    • Topical
    • Injectables
    • Drops
  • Global Active Pharmaceutical Ingredients Market, By Application:
    • Diabetes
    • Oncology
    • Cardiovascular
    • CNS
    • Analgesics
    • Ophthalmic
    • Respiratory
    • Dermatology
    • Others
  • Global Active Pharmaceutical Ingredients Market, By Region:
    • North America
      • By Product Type:
        • High Potent APIs
        • Low Potent APIs
      • By Molecule Type:
        • Small Molecules
        • Large Molecules
      • By Formulation:
        • Oral
        • Topical
        • Injectables
        • Drops
      • By Application:
        • Diabetes
        • Oncology
        • Cardiovascular
        • CNS
        • Analgesics
        • Ophthalmic
        • Respiratory
        • Dermatology
        • Others
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Product Type:
        • High Potent APIs
        • Low Potent APIs
      • By Molecule Type:
        • Small Molecules
        • Large Molecules
      • By Formulation:
        • Oral
        • Topical
        • Injectables
        • Drops
      • By Application:
        • Diabetes
        • Oncology
        • Cardiovascular
        • CNS
        • Analgesics
        • Ophthalmic
        • Respiratory
        • Dermatology
        • Others
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Product Type:
        • High Potent APIs
        • Low Potent APIs
      • By Molecule Type:
        • Small Molecules
        • Large Molecules
      • By Formulation:
        • Oral
        • Topical
        • Injectables
        • Drops
      • By Application:
        • Diabetes
        • Oncology
        • Cardiovascular
        • CNS
        • Analgesics
        • Ophthalmic
        • Respiratory
        • Dermatology
        • Others
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Product Type:
        • High Potent APIs
        • Low Potent APIs
      • By Molecule Type:
        • Small Molecules
        • Large Molecules
      • By Formulation:
        • Oral
        • Topical
        • Injectables
        • Drops
      • By Application:
        • Diabetes
        • Oncology
        • Cardiovascular
        • CNS
        • Analgesics
        • Ophthalmic
        • Respiratory
        • Dermatology
        • Others
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Product Type:
        • High Potent APIs
        • Low Potent APIs
      • By Molecule Type:
        • Small Molecules
        • Large Molecules
      • By Formulation:
        • Oral
        • Topical
        • Injectables
        • Drops
      • By Application:
        • Diabetes
        • Oncology
        • Cardiovascular
        • CNS
        • Analgesics
        • Ophthalmic
        • Respiratory
        • Dermatology
        • Others
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Product Type:
        • High Potent APIs
        • Low Potent APIs
      • By Molecule Type:
        • Small Molecules
        • Large Molecules
      • By Formulation:
        • Oral
        • Topical
        • Injectables
        • Drops
      • By Application:
        • Diabetes
        • Oncology
        • Cardiovascular
        • CNS
        • Analgesics
        • Ophthalmic
        • Respiratory
        • Dermatology
        • Others
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Teva Pharmaceutical Industries Ltd.*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Pfizer, Inc.
    • Endo International plc
    • Reddy’s Laboratories Ltd.
    • Novartis AG
    • Mylan N.V.
    • Amneal Pharmaceuticals LLC
    • Lonza Group
    • Stada Arzneimittel AG
    • Lupin Limited
    • Fresenius Kabi
    • Hikma Pharmaceuticals
    • Aurobindo Pharma Limited
    • Apotex Inc.
    • Cipla Limited
    • Taro Pharmaceutical Industries Ltd.
    • Biological E. Limited
    • CordenPharma International
    • Evonik Industries AG
    • Sun Pharmaceutical Industries Ltd.
    • Glenmark Pharma
    • Krka Pharmaceuticals

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Product Type
      • Market Snippet, By Molecule Type
      • Market Snippet, By Formulation
      • Market Snippet, By Application
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Regulatory Scenario
    • Market Trends
    • API Patent Expiration
    • Pipeline Analysis
    • ANDA/DMF Intelligence
    • Production Capability Analysis
    • Vertically Integrated Businesses
    • PEST Analysis
    • Reimbursement Scenario (Medicare Part D Spending)
  4. Global Active Pharmaceutical Ingredients Market – Impact of Coronavirus (COVID-19) Pandemic
    • Economic Impact
    • Manufacturing
    • Regulations
    • Government Measures to Combat COVID-19
  5. Global Active Pharmaceutical Ingredients Market, By Product Type, 2016 – 2027, (US$ Bn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • High Potent APIs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
    • Low Potent APIs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
  6. Global Active Pharmaceutical Ingredients Market, By Molecule Type, 2016 – 2027, (US$ Bn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Small Molecules
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
    • Large Molecules
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
  7. Global Active Pharmaceutical Ingredients Market, By Formulation, 2016 – 2027, (US$ Bn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
    • Topical
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
    • Injectables
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
    • Drops
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
  8. Global Active Pharmaceutical Ingredients Market, By Applic, 2016 – 2027, (US$ Bn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Diabetes
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
    • Oncology
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
    • Cardiovascular
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
    • CNS
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
    • Analgesics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
    • Dermatology
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
    • Respiratory
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
    • Ophthalmic
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Bn)
  9. Global Active Pharmaceutical Ingredients Market, By Region, 2016 – 2027, (US$ Bn)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2027
    • North America
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Molecule Type, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Formulation, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Bn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Molecule Type, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Formulation, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Bn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Molecule Type, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Formulation, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Bn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Molecule Type, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Formulation, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Bn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Molecule Type, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Formulation, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Bn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Molecule Type, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Formulation, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Bn)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Bn)
        • South Africa
        • Central Africa
        • North Africa
  10. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • Teva Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Endo International plc
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Reddy’s Laboratories Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Novartis AG
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Mylan N.V.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Amneal Pharmaceuticals LLC
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Lonza Group
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Stada Arzneimittel AG
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Lupin Limited
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Fresenius Kabi
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Hikma Pharmaceuticals
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Aurobindo Pharma Limited
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Apotex, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Cipla Limited
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Taro Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Biological E. Limited
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • CordenPharma International
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Evonik Industries AG
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sun Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Glenmark Pharma
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Krka Pharmaceuticals
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
  11. Section
    • Research Methodology
    • About us and Sales Contact

*Browse 39 market data tables and 35 figures on "Active Pharmaceutical Ingredients Market” - Global Forecast to 2027

Frequently Asked Questions

The global active pharmaceutical ingredients market size is estimated to be valued at US$ 180.4 billion in 2020 and is expected to exhibit a CAGR of 6.7% between 2020 and 2027.
The increasing prevalence of chronic diseases, geographic expansions by API manufacturers in Asia, and investment in research & development by manufacturers are expected to drive the market growth during the forecast period.
The low potent APIs segment is expected to be the leading segment in the global active pharmaceutical ingredients market.
North America is expected to hold the largest market share in the global active pharmaceutical ingredients market.
Strict regulatory scenario is a major factor restraining growth of the global active pharmaceutical ingredients market.
Major players operating in the global idiopathic hypersomnia treatment are Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Endo International plc, Dr. Reddy’s Laboratories Ltd., Novartis AG, Mylan N.V., Amneal Pharmaceuticals LLC, Lonza Group, Stada Arzneimittel AG, Lupin Limited, Fresenius Kabi, Hikma Pharmaceuticals, Aurobindo Pharma Limited, Apotex Inc., Cipla Limited, Taro Pharmaceutical Industries Ltd., Biological E. Limited, CordenPharma International, Evonik Industries AG, Sun Pharmaceutical Industries Ltd., Glenmark Pharma, and Krka Pharmaceuticals.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner